Video Experimental Relacionado
Updated: Jan 8, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.3K
Desarrollo Terapéutico Reciente Dirigido a Mutaciones KRAS en Cáncer Colorrectal
Hiromichi Ebi1, Sachiyo Shirakawa
1Precision Medicine Center, Aichi Cancer Center Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy
|December 24, 2025
Resumen
La terapia dirigida para el cáncer colorrectal (CCR) avanzado está evolucionando. Sotorasib, un inhibidor de KRAS G12C, ofrece una nueva esperanza para los pacientes con esta mutación específica, especialmente cuando se combina con anticuerpos anti-EGFR.
Área de la Ciencia:
- Oncología
- Biología Molecular
- Genética
Sus antecedentes:
- Las mutaciones KRAS son prevalentes en el cáncer colorrectal avanzado (CCR), lo que históricamente ha representado un desafío terapéutico.
- La proteína KRAS, particularmente la variante G12C, se consideraba ;intratable; debido a su estructura.
- Avances recientes han llevado al desarrollo de inhibidores dirigidos para mutaciones KRAS G12C.
Objetivo del estudio:
- Revisar la aplicación clínica de sotorasib, el primer inhibidor de KRAS G12C, en el tratamiento del cáncer colorrectal metastásico.
- Destacar la importancia de la terapia combinada con anticuerpos anti-EGFR para el CCR con mutación KRAS.
- Enfatizar el papel de las pruebas de mutación KRAS en la guía de las decisiones de tratamiento.
Principales métodos:
- Revisión de datos clínicos y guías terapéuticas para inhibidores de KRAS G12C en cáncer colorrectal.
- Análisis del mecanismo de acción de sotorasib y su combinación con terapias anti-EGFR.
- Discusión de estrategias diagnósticas para identificar mutaciones KRAS en pacientes con CCR.
Principales resultados:
- Sotorasib está aprobado para el cáncer colorrectal metastásico con mutación KRAS G12C, ofreciendo una nueva opción de terapia dirigida.
- La terapia combinada con inhibidores de KRAS y anticuerpos anti-EGFR es crucial para superar los mecanismos de resistencia.
- Se recomienda la prueba de mutación KRAS previa al tratamiento, incluida la G12C, para seleccionar pacientes apropiados.
Conclusiones:
- Sotorasib representa un avance significativo en el tratamiento del cáncer colorrectal con mutación KRAS G12C.
- Los enfoques de medicina personalizada, guiados por pruebas genéticas, están ampliando las opciones de tratamiento para el CCR avanzado.
- Las estrategias de combinación son esenciales para maximizar la eficacia terapéutica en el CCR con mutación KRAS.
Palabras clave:
sotorasibKRAS G12Ccáncer colorrectalterapia dirigidaanticuerpos anti-EGFRpruebas de mutaciónMás Videos Relacionados
06:19Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
Published on: July 18, 2017
10.6K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.5K
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:38The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:18Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K